Home / Psoriasis (page 3)


Here you will find the latest clinical research on psoriasis.

IL-23 Blocker for Psoriasis Successful in Extension Trials


GENEVA — Tildrakizumab, an investigational interleukin (IL)-23p19 inhibitor, appears to be effective for the treatment of chronic plaque psoriasis, according to long-term extensions of two phase 3 trials: reSURFACE1 and reSURFACE2 (Lancet. 2017;390:276-288). More than 80% of patients treated with tildrakizumab 200 mg for 2 years achieved a 75% reduction …

Read More »

Apremilast in psoriasis – A prospective real-world study


Vujic I, et al. – This paper strived to characterize psoriasis patients treated with apremilast in a real-world setting. In addition, it estimated the drug survival as a significant measure of efficacy and compliance. Variations were disclosed between real-world and trial patients. Nevertheless, apremilast was found to be safe and …

Read More »

Secukinumab safe and effective through 5 years in psoriasis


The improved skin clearance and favorable safety profile achieved with the interleukin-17A (IL-17A) inhibitor secukinumab is maintained through at least five years of treatment, new data suggest. The findings, presented here at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, are based on the patients originally …

Read More »

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis


Abstract Background Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. Objective To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. Methods We collected data on frequency of use, demographics, …

Read More »

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)


Blauvelt A, et al. – This paper scrutinized the efficacy and safety of ixekizumab through 108 weeks of treatment for moderate-to-severe plaque psoriasis. It was concluded that ixekizumab was well tolerated. It illustrated persistent efficacy through 108 weeks. Methods The enrollees (N = 1346) were randomized 2:2:2:1 to 80 mg …

Read More »

Psoriasis Severity Tied to Death Risk


The more that psoriasis covers the surface area of a body, the greater the risk of the patient’s death, according to a new analysis. Researchers in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia conducted the first study to link psoriasis severity to an increased risk …

Read More »

Guselkumab front and center at EADV Congress

edav dermatology conference

Due to the combination of efficacy, safety, and convenience, the interleukin (IL)-23 inhibitors will represent a “significant broadening” of the therapeutic armamentarium for moderate-to-severe psoriasis, according to Prof. Dr. Kristian Reich of Dermatologikum Hamburg in Hamburg, Germany. Dr. Reich spoke on how IL-23 inhibitors fit into the psoriasis treatment armamentarium in …

Read More »

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA (MUST)

  Purpose Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear. No data from Randomized Clinical Trials (RCTs) are available to address the questions whether add-on of MTX to …

Read More »